Marta Figueiredo, PhD, managing science editor —

Marta holds a biology degree, a master’s in evolutionary and developmental biology, and a PhD in biomedical sciences from the University of Lisbon, Portugal. She was awarded a research scholarship and a PhD scholarship, and her research focused on the role of several signaling pathways in thymus and parathyroid glands embryonic development. She also previously worked as an assistant professor of an annual one-week embryology course at the University of Lisbon’s Faculty of Medicine.

Articles by Marta Figueiredo

Eledon’s Antibody, Tegoprubart, Shows Promise in ALS Phase 2 Trial

Eledon Pharmaceuticals’ investigational antibody-based therapy, tegoprubart, safely and effectively reduces levels of inflammatory biomarkers in adults with amyotrophic lateral sclerosis (ALS), according to top-line data from a Phase 2a clinical trial. Exploratory findings suggested that lower levels of inflammatory biomarkers and whether tegoprubart’s target is significantly reduced,…

Radicava Oral Suspension Earns FDA Approval

The U.S. Food and Drug Administration (FDA) has approved Mitsubishi Tanabe Pharma America (MTPA)’s oral suspension formulation of edaravone, Radicava ORS, for the treatment of amyotrophic lateral sclerosis (ALS). The oral therapy is designed to offer the same efficacy as MTPA’s Radicava (edaravone) — an FDA-approved, into-the-vein therapy…

#AAN2022 – How Environmental Exposure Affects ALS Risk Is Studied

Researchers at the University of Michigan are focused on establishing cause and effect relationships between environmental and occupational exposures with amyotrophic lateral sclerosis (ALS). They hope this information will shed light on the mechanisms behind the disease and identify modifiable risk factors, which may have implications in preventing ALS.